Learning Modules :: NYS Clinical Education Initiative

Home > Learning Modules

Learning Modules

The presentations listed below can be viewed online for educational purposes. You will not be given CME credit for watching them. To earn online CME credit, you must log into the CEI Student Portal.

Update from the 2013 Conference on Retroviruses and Opportunistic Infections (20th CROI)

Charles Hicks, MD
Professor of Medicine
Duke University Medical Center

Presentation Date: 04/04/2013

Release Date: 04/15/2013

Course Overview

Clinical Manifestations of the Most Common STDs

Shelley Gilroy, MD, AAHIVS
Associate Professor of Medicine, Division of HIV Medicine
Albany Medical College

Presentation Date: 03/07/2013

Release Date: 03/19/2013

Course Overview

HIV Treatment as Prevention: Ethics, Policy, and Implementation in the New York Region

Treatment as Prevention with People Living with HIV

Robert Remien, PhD
HIV Center for Clinical and Behavioral Studies
NYS Psychiatric Institute and Columbia University
Thomas Coates, PhD
David Geffen School of Medicine at UCLA
R. Scott Braithwaite, MD, MSc
NYU School of Medicine

Presentation Date: 10/12/2012

Release Date: 03/12/2013

Treatment as Prevention for the Uninfected

Crystal Fuller, PhD, MPH
Mailman School of Public Health
Columbia University
Bruce Schackman, PhD
Weill Cornell Medical College
Roy Gulick, MD, MPH
Weill Cornell Medical College

Presentation Date: 10/12/2012

Release Date: 03/12/2013

Government Policy Perspectives

Guthrie Birkhead, MD, MPH
New York State Department of Health
Jay Varma, MD
New York City Department of Health and Mental Hygiene

Presentation Date: 10/12/2012

Release Date: 03/12/2013

Research Update on HIV Treatment as Prevention

Myron Cohen, MD
University of North Carolina

Presentation Date: 10/12/2012

Release Date: 03/12/2013

Ethical and Policy Implications of HIV Treatment as Prevention

Celia Fisher, PhD
Fordham University
Robert Klitzman, MD
Mailman School of Public Health
Columbia University
Daniel Raymond
Harm Reduction Coalition
Richard Jefferys
Treatment Action Group

Presentation Date: 10/12/2012

Release Date: 03/12/2013

Use of Motivational Interviewing in HIV Care: Theory into Practice

Sanjiv Shah, MD, MPH
North Shore University Hospital

Presentation Date: 05/17/2012

Release Date: 02/22/2013

Course Overview

Health & Human Rights: Our Experience in the Challenges of Combating HIV/AIDS

Kamiar Alaei, MD
HIV/AIDS, TB and Harm Reduction Expert
University at Albany
Arash Alaei, MD
HIV/AIDS, TB and Harm Reduction Expert
University at Albany

Presentation Date: 02/14/2013

Release Date: 02/21/2013

Course Overview

PrEP: Promises, Challenges & Ethics

Jason Leider, MD, PhD
Associate Professor of Clinical Medicine,Albert Einstein College of Medicine, Yeshiva University
Medical Director of the North Bronx Health Care Network

Presentation Date: 02/07/2013

Release Date: 02/21/2013

Course Overview

HIV Immune Reconstitution Inflammatory Syndrome (IRIS): pathogenesis and pearls for clinical management [CE Available]

David Boulware, MD, MPH, CTropMed
Lois & Richard King Distinguished Assistant Professor
University of Minnesota

Presentation Date: 06/19/2012

Release Date: 02/01/2013

Co-sponsor:

Course Overview

Learning Objectives

Recognize risk factors for immune reconstitution inflammatory syndrome (IRIS).
Distinguish IRIS from other mimics.
Understand clinical management and treatment of IRIS.

Presenter Bio

Dr. Boulware serves as the Associate Director of Global Health Programs in Internal Medicine at the University of Minnesota, and his research interest is in understanding the pathogenesis of HIV immune reconstitution inflammatory syndrome (IRIS). In particular, Dr. Boulware is most interested in translational research of disease pathogenesis leading to practical clinical interventions to improve outcomes. In collaboration with investigators at Makerere University and Mbarara University in Uganda, and at the University of Cape Town, in South Africa, Dr Boulware is working to improve the survival of persons with cryptococcal meningitis by identifying the optimal time to start HIV therapy after meningitis (NCT01075152). Through this trial, Dr.Boulware’s collaborative research involves characterizing the differences in immune responses that occur over time among people who develop IRIS, in an effort to identify the pathophysiology of IRIS, identify biomarkers for the prediction and diagnosis of IRIS, develop better treatments, and to prevent IRIS.

HIV-1 Pathogenesis and the GI Tract: The Effects of Colorectal Immune Deficiency & Reconstitution [CE Available]

Saurabh Mehandru, MD
Assistant Professor; Visiting Scientist, The Aaron Diamond AIDS Research Center
Mount Sinai School of Medicine

Presentation Date: 06/19/2012

Release Date: 02/01/2013

Co-sponsor:

Course Overview

Learning Objectives

Understand the functional and anatomic organization of the GI immune system and its relevance to the pathogenesis of HIV-1 infection.
Appreciate the impact of acute and chronic HIV-1 on the GI immune system.
Know the effect of prolonged antiretroviral therapy on GI immune reconstitution and its potential clinical implications.

Presenter Bio

Saurabh Mehandru is an Assistant Professor of Gastroenterology at the Mount Sinai School of Medicine in New York City. Saurabh’s research interests include study of the gastrointestinal immune system in HIV infection. He trained at the Aaron Diamond AIDS Research Center in the laboratory of Dr. Martin Markowitz where he described the early and preferential depletion of GI CD4+ T cells during acute HIV infection and the incomplete reconstitution of intestinal CD4 T cells with ART. Saurabh then worked in the laboratory of Dr. Ralph Steinman, where using novel HIV vaccines, he focused on the generation of intestinal immunity against HIV.

Partnership for Health Orientation

Alexandra Levine, MD
Distinguished Professor of Medicine
University of Southern California

Presentation Date: 01/16/2013

Release Date: 01/21/2013

Course Overview

Clostridium Difficile: New Problems with an Old Disease

Sarah Elmendorf, MD
Albany Medical Center

Presentation Date: 01/03/2013

Release Date: 01/15/2013

Assess, Screen & Treat: Incorporating STD Care into Your Medical Practice

L. Jeannine Bookhardt-Murray, MD
Chief Medical Officer
Harlem United, Upper Room AIDS Ministry

Presentation Date: 12/03/2012

Release Date: 01/10/2013

Course Overview

Preventing and Managing Kidney Disease in HIV-Infected Patients [CE Available]

Christina Wyatt, MD
Assistant Professor of Medicine, Department of Nephrology
Mount Sinai School of Medicine, New York, NY

Presentation Date: 05/23/2012

Release Date: 01/10/2013

Co-sponsor:

Course Overview

Learning Objectives

Identify HIV-infected individuals who may be at higher risk for kidney disease.
Recognize the limitations of current screening tests for kidney disease and nephrotoxicity in HIV-infected individuals.
Understand the diagnosis and management of ART nephrotoxicity.

Presenter Bio

Christina Wyatt’s clinical and research interests focus on acute and chronic kidney disease in patients with HIV and hepatitis C. Ongoing projects include a prospective research cohort in Mount Sinai's active HIV practice, as well as two studies investigating the utility of currently available GFR estimates in patients with HIV infection. Study objectives in the HIV cohort include description of the prevalence, incidence, and predictors of acute and chronic kidney disease in the era of antiretroviral therapy, as well as improved understanding of the impact of HCV co-infection on the risk for kidney disease.

What Do We Really Know About Cardiovascular Disease in the HIV-infected Population? [CE Available]

Samir Gupta, MD, MS
Associate Professor of Medicine, Division of Infectious Diseases
Indiana University School of Medicine

Presentation Date: 05/23/2012

Release Date: 01/09/2013

Co-sponsor:

Course Overview

Learning Objectives

Compare the epidemiology of cardiovascular disease in those with and without HIV infection.
Differentiate the contributions of HIV medications vs. the infection itself on cardiovascular disease.
Predict which interventions may reduce the increased risk of cardiovascular disease in HIV-infected patients.

Presenter Bio

Samir Gupta is an HIV care provider at the Wishard Memorial Hospital (the county hospital for Indianapolis) and has participated in clinical research focusing on the effects of HIV and ART on renal and cardiovascular diseases. Dr. Gupta receives funding from both the NIH and industry to support these ongoing research efforts. In particular, Dr. Gupta is the Principal Investigator for one of the NIH-CVD collaborative research programs.

Controversies in HIV Medicine 2012

Calvin Cohen, MD, MSc
Research Director for the Community Research Initiative of New England and Harvard Vanguard Medical Associates
Harvard Medical School

Presentation Date: 12/06/2012

Release Date: 12/17/2012

Course Overview

Pharmacists: A Valuable Part of the HIV Treatment Team

John Faragon, PharmD, BCPS, AAHIVE
NY/NJ AETC Regional Pharmacy Director
Albany Medical Center

Presentation Date: 06/03/2012

Release Date: 12/14/2012

Course Overview

Learning Objectives

Compare the preferred HIV regimens by the U.S. Department of Health and Human Services (DHHS) for the initial management of HIV infection.
Discuss why HIV infection should be treated earlier than previous versions of the DHHS Guidelines.
Describe the role of the pharmacist in HIV care as it relates to side effect management, adherence counseling, and medication error reduction.
PLEASE NOTE: CONTINUING PHARMACY EDUCATION CREDIT FOR THIS COURSE IS THROUGH ACPE. PLEASE FOLLOW THE INSTRUCTIONS BELOW TO GET YOUR CONTINUING PHARMACY EDUCATION CREDIT.

ACPE Credit: For continuing pharmacy education credit through the Accreditation Council for Pharmacy Education, please print out and follow the instructions at: http://www.ceiconnect.org/pharmacistsjune2012

Presenter Bio

John J. Faragon is currently the Regional Pharmacy Director for NY/NJ AIDS Education and Training Centers and a Pharmacist with the Department of Pharmacy at Albany Medical Center Hospital in Albany, New York. Previously, John Faragon has held positions in pharmacy practice, academia and in the pharmaceutical industry. He is certified in Pharmacotherapy by the Board of Pharmaceutical Specialists from the American College of Clinical Pharmacy and certified as a subject matter expert from the American Academy of HIV Medicine.

Head and Neck Exam for Healthcare Providers

Gwen Cohen-Brown, DDS
Associate Professor
New York City College of Technology

Presentation Date: 11/08/2012

Release Date: 11/13/2012

Course Overview

Depression as a Medical Co-morbidity of HIV Infection

James Satriano, Ph.D.
Assistant Professor of Clinical Psychology
Columbia University

Presentation Date: 10/25/2012

Release Date: 11/13/2012

Course Overview

Metabolic Complications of HIV (and Antiretroviral Therapy)

Marshall Glesby, MD, PhD
Professor of Medicine
Weill Cornell Medical College

Presentation Date: 10/25/2012

Release Date: 11/01/2012

Course Overview

HIV and Aging

Sanjiv Shah, MD, MPH
North Shore University Hospital

Presentation Date: 10/25/2012

Release Date: 10/31/2012

Course Overview

Transgender Treatment in High Risk Adolescents

Jeffrey Birnbaum, MD, MPH
Associate Professor of Pediatrics & Public Health
SUNY Downstate Medical Center

Presentation Date: 11/17/2011

Release Date: 10/18/2012

Gene Therapy Studies for the Treatment of HIV Infection [CE Available]

Pablo Tebas, MD
Director, AIDS Clinical Trials Unit (ACTU)
University of Pennsylvania

Presentation Date: 04/24/2012

Release Date: 09/27/2012

Co-sponsor:

Course Overview

Learning Objectives

Know the different gene therapy approaches that are being taken to treat HIV infection and the role of zinc finger nucleases.
Discuss the potential side effects of these approaches.
Understand other potential strategies beyond gene therapy to control HIV in the absence of antiretroviral therapy.

Presenter Bio

Pablo Tebas directs the adult AIDS Clinical Trials Unit (ACTU) of the University of Pennsylvania. His main research interests are the treatment of HIV infection and the study of the metabolic complications associated with HIV infection and its treatment The introduction of highly active antiretroviral therapy has resulted in significant reductions in the morbidity and mortality associated with HIV infection. Unfortunately, the use of HAART has also been associated with significant adverse effects, including dyslipidemia and insulin resistance, bone disease and fat redistribution. Current studies are directed to understand better the mechanisms of these complications and prevent their development. Current outpatient and inpatient clinical activities center in the Hospital of the University of Pennsylvania where he follows general ID and HIV infected patients.

The Berlin Patient: Eradication of HIV with CCR5 deficient hematopoietic stem cells [CE Available]

Gero Hütter, MD
Production Manager, Institute of Transfusion Medicine and Immunology
Heidelberg University, Mannheim, Germany

Presentation Date: 04/24/2012

Release Date: 09/24/2012

Co-sponsor:

Course Overview

Learning Objectives

Understand the strategy of stem cell transplantation in HIV patients.
Know the importance of CCR5 for maintaining HIV infection.
Discuss the topics of functional and sterilizing cure.

Presenter Bio

Gero Hütter developed and performed the first allogeneic bone marrow transplantation with natural CCR5 depleted stem cells in a leukemia patient with HIV-infection in 2004, during his residency in hematology, oncology and transfusion medicine at Charité Hospital in Berlin, Germany. Since then, Timothy Brown, now known as “the Berlin patient,” has not resumed antiretroviral therapy, nor has he had a relapse of HIV disease. In 2009 Dr Hütter became the head of the stem cell unit of the Institute of Transfusion Medicine and Immunology Mannheim of the Heidelberg University. There, he directs the research group for personalized stem therapy, which is supported by a grant from the Bill & Melinda Gates foundation.

Interactions between HIV and the Host Cell: Latency or Virus Production?

Karen Duus, Ph.D.
Center for Immunology and Microbial Disease
Albany Medical College

Presentation Date: 09/06/2012

Release Date: 09/07/2012

HIV/AIDS and Post-Traumatic Stress Disorder (PTSD)

Francine Cournos, MD
Professor of Clinical Psychiatry (in Epidemiology)
Columbia University, College of Physicians and Surgeons

Presentation Date: 08/14/2012

Release Date: 08/14/2012

Course Overview

Learning Objectives

Understand DSM criteria for PTSD and how to screen for the disorder
Identify HIV-related medical and psychiatric rule-outs for establishing the diagnosis
Recognize antecedents and sequelae of PTSD that affect health and risk behaviors
Implement effective strategies for reducing the impact of PTSD on HIV course

Presenter Bio

Francine Cournos, MD is Professor of Clinical Psychiatry at Columbia University. She is the Director of the Washington Heights Community Service at New York State Psychiatric Institute, a program funded by the New York State Office of Mental Health. Dr. Cournos is the Principal Investigator of the New York/New Jersey AIDS Education and Training Program and she has worked in the area of HIV/AIDS and mental illness since 1983. Dr. Cournos has participated in numerous research projects, training grants, practice guidelines, and policy development projects.

HIV Testing in Emergency Department Settings

Daniel Egan, MD, FACEP
Associate Program Director
St. Luke's Roosevelt Hospital

Presentation Date: 07/23/2012

Release Date: 08/13/2012

Course Overview

HIV Testing Update: New Regulations And Strategies from the Field

Daniel Egan, MD, FACEP
Associate Program Director
St. Luke's Roosevelt Hospital
Daniel O'Connell
Deputy Director
New York Department of Health’s AIDS Institute
Debbie Lester, LMSW

Presentation Date: 05/17/2012

Release Date: 07/31/2012

Course Overview

Presenter Bio

Daniel J. Egan, MD, is the Associate Program Director at St. Luke’s Roosevelt Hospital Center and Assistant Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons. Dr. Egan graduated from the Mount Sinai School of Medicine and completed his residency training at the Harvard Affiliated Emergency Medicine Residency Program at Brigham & Women’s/Massachusetts General Hospital. Dr. Egan’s main interests are HIV testing in the ED and HIV Post-Exposure Prophylaxis. He is a faculty member for the NY AIDS institute Clinical Education Initiative and has lectured around NY on these topics.

13th Annual HIV Clinical Symposium

Overview of Drug Interactions with Hepatitis C Protease

John Faragon, PharmD, BCPS, AAHIVE
NY/NJ AETC Regional Pharmacy Director
Albany Medical Center

Presentation Date: 06/06/2012

Release Date: 06/06/2012

Course Overview

Oral Health and the Primary Care Provider

Stephen Abel, DDS, MSD
Associate Dean for Extramural and Public Health Programming
College of Dental Medicine, Nova Southeastern University

Presentation Date: 06/06/2012

Release Date: 07/30/2012

HIV Prevention with Antiretroviral Agents: How To Predict Success? [CE Available]

Angela Kashuba, BScPhm, PharmD, DABCP
Associate Professor
University of North Carolina School of Pharmacy

Presentation Date: 03/27/2012

Release Date: 07/20/2012

Co-sponsor:

Course Overview

Learning Objectives

Review the completed and ongoing clinical trials that use antiretroviral agents for HIV prevention.
Outline potential reasons for the current discrepant clinical trial results.
Discuss agents and modes of delivery currently in the HIV prevention pipeline.
Review future strategies and optimal clinical trial designs for HIV chemoprophylaxis.

Presenter Bio

Angela Kashuba has been on faculty at the University of North Carolina at Chapel Hill since 1997, and is currently an Associate Professor in the UNC School of Pharmacy, and directs both the UNC Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core and the Pharmacology Core for the UNC Delaney Collaboratory. She is a Diplomate of the American Board of Clinical Pharmacology and was the 2009 recipient of the Leon I. Goldberg Young Investigator Award from the American Society of Clinical Pharmacology and Therapeutics. Dr. Kashuba has authored over 110 publications and has received ~$12 million in research funding. Her research is focused on utilizing antiretrovirals to prevent HIV transmission, and she is currently involved in evaluating drug concentration-effect relationships in CAPRISA 004 and FEMPrEP.

Strategies (and New Agents) for Antiretroviral Therapy of HIV-1 Disease [CE Available]

Roy Gulick, MD, MPH
Professor of Medicine and Chief of the Division of Infectious Diseases
Weill Medical College of Cornell University in New York City

Presentation Date: 03/27/2012

Release Date: 07/20/2012

Co-sponsor:

Course Overview

Learning Objectives

Understand the evolving recommendations for when to start antiretroviral therapy (ART) for HIV disease.
Identify optimal initial ART regimens.
Know strategies for treatment-experienced patients.
Learn about new antiretroviral agents for the treatment of HIV disease.

Presenter Bio

Dr. Gulick is Professor of Medicine and Chief of the Division of Infectious Diseases at Weill Medical College of Cornell University in New York City. He currently serves as Principal Investigator of the Cornell HIV Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG), sponsored by the National Institutes of Health. He also serves as a Board Member of the International AIDS Society-USA, and as a member of the Panel on Clinical Practices for Treatment of HIV Infection of the U.S. Department of Health and Human Services.

Historical Clues, Physical Signs, Laboratory Diagnosis & Treatment of Oral, Anogenital & Systemic STDs [CE Available]

Thomas Cherneskie, MD, MPH
Supervising Physician
NYC Department of Health & Mental Hygiene

Presentation Date: 02/28/2012

Release Date: 07/20/2012

Co-sponsor:

Course Overview

Learning Objectives

Make better use of sexual history in the examination of oral, anogenital, skin and systemic complaints of patients with or at risk for HIV disease.
Understand the differential diagnosis and appropriate diagnostic studies in evaluation of skin, oral and anogenital lesions suggestive of sexually transmitted infections.
Know preferred treatments of common STIs, and appropriate partner notification and follow-up.
Better counsel patients on the relative risk of concomitant HIV transmission associated with other STIs.

Presenter Bio

THOMAS CHERNESKIE is a graduate of the Penn State College of Medicine, following which he continued his training in Family Medicine and more recently Preventive Medicine & Public Health, obtaining an Master in Public Health from the Columbia University Mailman School of Public Health. His practice history includes outpatient urban primary care, occupational medicine, and currently serves as the supervising physician at one of NYC Department of Health & Mental Hygiene’s Sexual Health Clinics. He has nearly 15 yrs. of experience in the field of Sexually transmitted diseases and continues to share his expertise as a faculty member, and founding Medical Director, of the Region II CDC-funded STD/HIV Prevention Training Center.

Primary-Care Diagnosis and Treatment of Common Dermatological Problems in HIV Medicine [CE Available]

N. Hennessey, MD
Associate Clinical Professor
NYU School of Medicine

Presentation Date: 02/28/2012

Release Date: 07/20/2012

Co-sponsor:

Course Overview

Learning Objectives

Recognize the dermatological signs of acute HIV.
Be more familiar with common dermatological presentations in chronic and advanced HIV disease.
Understand primary-care diagnosis and treatment approaches to common HIV-related dermatological problems, and when to refer to a specialist.

Presenter Bio

PATRICK HENNESSEY is an associate clinical professor at the NYU School of Medicine, with additional teaching appointments at SUNY Downstate & the New York College of Osteopathic Medicine. Dr. Hennessey is a member of the medical staffs of NYU Tisch, Long Island College & Southampton Hospitals with private practices in New York City & the Hamptons. Dr. Hennessey graduated from Michigan State University College of Human Medicine with residencies in medicine at New England Deaconness Hospital in Boston and dermatology at New York University Medical Center. Dr. Hennessey also completed a post graduate fellowship in malignant melanoma and has continued his interest in cutaneous malignancies and HIV-related skin diseases with over 25 publications in these areas.

HIV Infection: Worse the Second Time? [CE Available]

Davey Smith, MD, MAS
Medical Director, Early Intervention Program
University of California San Diego

Presentation Date: 12/13/2011

Release Date: 07/20/2012

Co-sponsor:

Course Overview

Learning Objectives

Know the differences between HIV-1 co-infection and superinfection.
Understand who might be at risk for superinfection.
Discuss what superinfection might mean clinically.
Realize what superinfection might mean for preventive vaccine efforts.

Presenter Bio

Davey Smith is a translational research virologist. He uses basic science techniques to answer clinically relevant questions and vice-versa. He works both at the UCSD Antiviral Research Center where he is the medical director of the Early Intervention Program and in his laboratory on the UCSD campus where he performs bench research and he runs the Centers for AIDS Research Translational Virology Core. His primary research focus is on the transmission of HIV, including HIV superinfection and characterizing HIV shed from the genital tract. These studies are in pursuit to understand the correlates that drive HIV transmission and find new ways to interrupt them. In October, 2010, Dr. Smith was named HIV Researcher of the Year by the HIV Medical Association.

Hypogonadism in Older HIV-Infected Men: Current Concepts and Controversies [CE Available]

Todd Brown, MD, PhD
Associate Professor of Medicine
Johns Hopkins University

Presentation Date: 12/13/2011

Release Date: 07/20/2012

Co-sponsor:

Course Overview

Learning Objectives

Discuss the optimal screening recommendations regarding hypogonadism and the current controversies.
Discuss the potential risks and benefits of testosterone therapy, particularly with respect to the older male.

Presenter Bio

Todd T. Brown is an Associate Professor of Medicine in the Division of Endocrinology and Metabolism at Johns Hopkins University where he is also the primary endocrine consultant to the Johns Hopkins HIV Clinic. His research focuses on metabolic, endocrine, and skeletal abnormalities observed in HIV-infected patients, particularly as related to aging. Dr Brown is Chair of the Metabolic Working Group in the Multicenter AIDS Cohort Study and was appointed by the AIDS Clinical Trial Group to their newly formed Inflammation/End-organ Disease Transformative Science Group.

Gastrointestinal Disease in HIV Infection [CE Available]

Donald Kotler, MD
Chief, Division of Gastroenterology and Liver Disease
St. Luke's-Roosevelt

Presentation Date: 11/15/2011

Release Date: 07/20/2012

Co-sponsor:

Course Overview

Learning Objectives

Describe the heterogeneity of the HIV-infected population of New York City and its varied effects on GI disease.
Review the clinical manifestations of HIV-associated and selected non-HIV associated GI diseases that affect our patients.
Utilize algorithms for the evaluation of specific clinical GI syndromes.

Presenter Bio

Donald P. Kotler is a gastroenterologist, an expert on GI manifestations of HIV disease, and a pioneer in the study of the AIDS wasting syndrome. Dr. Kotler has concentrated on the study of body composition in order to define the characteristics of malnutrition in HIV infection and other diseases, as well as strategies to reverse the wasting process. He has been the Principal investigator on single-site and multi-center studies of nutritional therapies for HIV-associated malnutrition. In addition, Dr. Kotler has studied the opportunistic enteric complications of AIDS as well as the role of HIV as an enteric pathogen. More recently, he has studied the body composition and metabolic abnormalities associated with lipodystrophy, and is applying his knowledge and laboratory techniques to the study of chronic liver disease.

Clinical Management of Hepatitis C in Patients With and Without HIV Coinfection [CE Available]

Andrew Talal, MD, MPH
Associate Medical Director
Center for the Study of Hepatitis C at the Weill Cornell Medical College

Presentation Date: 10/11/2011

Release Date: 06/29/2012

Co-sponsor:

Course Overview

Learning Objectives

Understand the current approach to the diagnosis and staging of hepatitis C virus (HCV) infection.
Know how HIV/HCV coinfection affects HCV pathogenesis.
Appreciate treatment outcomes and side effect management to pegylated interferon and ribavirin in both HCV monoinfected and HIV/HCV coinfected individuals.

Presenter Bio

Andrew Talal is Associate Professor of Medicine and Associate Medical Director at the Center for the Study of Hepatitis C at the Weill Cornell Medical College. Following his research fellowship in Gastrointestinal Epidemiology at the University of North Carolina at Chapel Hill, Dr Talal became a Rockefeller University Clinical Scholar in the laboratory of Dr. David Ho where he investigated the pathogenesis of HIV in the gut associated lymphoid tissue. In February 2000, Dr. Talal joined the faculty at Weill Cornell where he founded the Viral Hepatitis Clinic, the Center’s Translational Research Laboratory. His research interests include investigation of chemokines as mediators of fibrogenesis and noninvasive biomarkers of hepatic fibrosis. He also has been interested in HCV management in disenfranchised populations including HIV/HCV coinfected and those on opiate agonist therapy.

Learning From HIV: Pharmacology's Role in the Management of Hepatitis C [CE Available]

Charles Flexner, MD
Professor of Medicine and Pharmacology
Johns Hopkins University School of Medicine

Presentation Date: 10/11/2011

Release Date: 06/29/2012

Co-sponsor:

Course Overview

Learning Objectives

Know the clinical importance of pharmacologic factors in the management and control of HCV infection with and without HIV-coinfection.
Understand possible approaches to managing clinically significant drug-drug interactions involving new directly-acting agents (DAA) for HCV.
Discuss similarities and differences in the pharmacologic management of hepatitis virus infections as compared to HIV.

Presenter Bio

Charles W. Flexner is Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences in the Johns Hopkins University School of Medicine. He is also Professor of International Health in the Johns Hopkins University Bloomberg School of Public Health. Dr. Flexner is an acknowledged expert on the basic and clinical pharmacology of drugs for HIV/AIDS and related infections, including viral hepatitis and tuberculosis. His scientific contributions include work on the important roles of pharmacokinetic enhancement, adherence, and dosing frequency in the long-term management of HIV/AIDS. He has also published extensively on anti-infective drug transport and metabolism, and metabolic drug interactions. Dr. Flexner is the Principal Investigator of the Johns Hopkins University AIDS Clinical Trials Unit (ACTU) supported by the NIH, and is Chair of the AIDS Clinical Trials Group (ACTG) Translational Research and Drug Development (TRADD) Committee.

New Insights in Hepatitis B and HIV Coinfection [CE Available]

Marion Peters, MD
ACTG Hepatitis Transformative Science Group

Presentation Date: 09/13/2011

Release Date: 06/29/2012

Co-sponsor:

Course Overview

Learning Objectives

Understand how to diagnose and treat HBV coinfection in HIV-positive patients.
Know the causes of HBV reactivation in HIV coinfected patients.
Monitor and manage end-stage liver disease in HBV- and HIV-infected patients.

Presenter Bio

Marion Peters, MD, is a hepatologist who is particularly interested in viral hepatitis. She has performed many studies of HBV infection, most recently the knowledge and screening among family members of Hepatitis B infected Asians in San Francisco. She leads the ACTG Hepatitis Transformative Science Group and the Women’s Interagency HIV study (WIHS) Hepatitis Working Group. She is studying new serum markers to evaluate liver fibrosis in WIHS. She is particularly interested in studying outcomes in Hepatitis B and new HCV drugs for patients with HCV, with and without HIV.

Update on Solid Organ Transplantation in People with HIV Infection [CE Available]

Michelle Roland, MD
Chief of the Office of AIDS
California Department of Health

Presentation Date: 09/13/2011

Release Date: 06/29/2012

Co-sponsor:

Course Overview

Learning Objectives

Know the patient and graft outcomes among 150 HIV-positive kidney recipients followed prospectively, including the challenges with transplant rejection and management of drug interactions and potential nephrotoxicities.
Understand predictors of mortality and implications for patient selection among 125 HIV-positive liver transplant recipients.
Discuss HIV-specific outcomes and predictors among the entire cohort of 275 HIV-positive liver and kidney recipients, all followed for a minimum of 1 year.

Presenter Bio

Michelle Roland, MD, is Chief of the Office of AIDS, California Department of Health, and Associate Clinical Professor of Medicine in the Department of Medicine, UCSF Positive Health Program (HIV/AIDS Division) at San Francisco General Hospital. In addition to her leadership in non-occupational post-exposure prophylaxis research, Dr Roland developed and implemented pilot studies that led to an NIH-funded, 21-center study of kidney and liver transplantation in people living with HIV, for which she served as co-principle investigator and lead HIV physician.

Clinical Diagnosis and Treatment of Common Anorectal Disease in MSM [CE Available]

Stephen Goldstone, MD, FACS
Assistant Clinical Professor of Surgery
Mount Sinai School of Medicine

Presentation Date: 08/09/2011

Release Date: 06/25/2012

Co-sponsor:

Course Overview

Learning Objectives

Understand important history-taking questions to aid in diagnosing common anorectal disorders in MSM.
Identify common anorectal disorders during physical examination in MSM.
Understand the best treatment options for common anorectal disorders in MSM.

Presenter Bio

Stephen Goldstone, MD, FACS is an Assistant Clinical Professor of Surgery at the Mount Sinai School of Medicine and has a surgical practice in New York City. He has developed a surgical technique to treat anal HPV dysplasia and is a member of the AIDS Malignancy Consortium. Dr. Goldstone is an expert on gay men's health, and has done extensive research on human papillomavirus (HPV), including prevention and treatment procedures for HPV.

The Path to Anal Cancer Prevention: Where We Are and Where We're Going [CE Available]

Joel Palefsky, MD, CM, F.R.C.P.(C)
Professor of Medicine
University of California San Francisco School of Medicine

Presentation Date: 08/09/2011

Release Date: 06/25/2012

Co-sponsor:

Course Overview

Learning Objectives

Understand the epidemiology of anal cancer in the post-ART era.
Understand current approaches to anal cancer screening and their limitations.
Understand the role of HPV vaccination in anal cancer prevention.

Presenter Bio

Dr. Joel Palefsky is a Professor of Medicine at the University of California San Francisco School of Medicine, and an expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the Director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic at the UCSF Cancer Center, and chair of the HPV Working Group of the U.S. National Cancer Institute-supported AIDS Malignancy Consortium. He is the founder of the newly established International Anal Neoplasia Society and is the president-elect of the International Papillomavirus Society.

22nd HIV/AIDS Clinical Conference: What's Working Today

Biomedical Nanotechnology: Emerging Tools for Improving Human Health

Benjamin Miller, PhD
Professor of Dermatology, Biochemistry and Biophysics, and Biomedical Engineering
University of Rochester School of Medicine and Dentistry

Presentation Date: 05/25/2012

Release Date: 06/21/2012

Course Overview

Learning Objectives

Discuss what biomedical nanotechnology is, and how it is likely to impact research and clinical care in the next decade
Explain how semiconductor nanoparticles and magnetic nanoparticles can provide new, high-resolution images in a broad range of diagnostic applications.
Describe how new chip-based rapid diagnostic technology will allow for rapid point-of-care diagnosis of viral infections, and analysis of immune system function.

Presenter Bio

Benjamin Miller<cfif len(qPresenters.presenter_credential)>, PhD</cfif>

Dr. Miller is a Professor of Dermatology, Biochemistry and Biophysics, and Biomedical Engineering at the University of Rochester. He completed his undergraduate studies at Miami University, receiving degrees in Chemistry (BS), Mathematics (BA), and German (BA). He received his PhD in Chemistry from Stanford University. Dr. Miller joined the University of Rochester faculty in 1996. Research in the Miller group focuses on two fundamental areas: the control of biomolecular interactions through the synthesis of new small-molecule probes, and the observation of biomolecular interactions through the development of novel optical sensing technologies.

An Update: HIV Confidentiality & Patient Care in 2012

Ann Weisbeck, MS, FNP
Nurse Practitioner
University of Rochester Medical Center
Julie Miller, LMSW
AIDS Clinic, University of Rochester Medical Center

Presentation Date: 05/25/2012

Release Date: 06/21/2012

Course Overview

Learning Objectives

Explain why HIV/AIDS-related information is protected health information.
Describe situations in which NYSDOH guidelines permit health professionals to share a patient’s HIV/AIDS-related information.
Identify situations in which NYSDOH guidelines forbid health professionals to share a patient’s HIV/AIDS-related information.

Presenter Bio

Anne M. Weisbeck is a Nurse Practitioner in the AIDS Center, University of Rochester Medical Center. She provides health care/management for patients with HIV/AIDS, post exposure prophylaxis treatment and follow up for patients potentially exposed to HIV. She is also involved in peer and community education on HIV related topics.

Wireless Technology and Treatment for HIV/AIDS

Kevin Fiscella, MD, MPH
Professor of Medicine
University of Rochester School of Medicine and Dentistry

Presentation Date: 05/25/2012

Release Date: 06/21/2012

Course Overview

Learning Objectives

Describe how software and wireless technology can improve health outcomes.
Explain how HIV/AIDS patients can use wireless technology to help them remain adherent to treatment.
Discuss future applications of treatment software and wireless technology currently under investigation.

Presenter Bio

Kevin Fiscella<cfif len(qPresenters.presenter_credential)>, MD, MPH</cfif>

Dr. Fiscella received his BA in psychology from Antioch College, his MD from the Medical College of Virginia, and his MPH degree from the University of Rochester. He completed a faculty development fellowship through the University of Rochester Department of Family Medicine, training in family therapy through the Department of Psychiatry and joined the faculty in 1996. He is Associate Director of the Rochester Center to Improve Communication in Health, Co-Director of Community Engagement for the Rochester Clinical Translational Science Institute, Co-Director of the Greater Rochester Practice Research Network and HIV Clinical Coordinator for Westside Community Health Center. His clinical interests are in the area of care of chemically dependent HIV+ persons and office management of chronic pain. His research interests are in the area of racial and socioeconomic disparities in health status, the effects of poverty on family function, and health services to under-served populations, particularly those at risk for cancer and heart disease. He is currently directing projects funded by the American Cancer Society, National Cancer Institute, and National Heart Lung and Blood Institute.

An Update on HIV & Bone Disease

Krupa Shah, MBBS, MPH
Assistant Professor
Center for Bone Health, University of Rochester Medical Center

Presentation Date: 05/25/2012

Release Date: 06/21/2012

Course Overview

Learning Objectives

Describe data that suggests immune reconstitution may play a major role in antiretroviral therapy-related bone loss.
Explain how HIV viral proteins may affect osteoblast and osteoclast function.
Explain how to screen for patients at high risk for osteoporosis and recommendations for preventing bone loss.

Presenter Bio

Krupa Shah<cfif len(qPresenters.presenter_credential)>, MBBS, MPH</cfif>

Dr. Krupa Shah is a board-certified geriatrician in the Dept of Medicine and the Dept of Orthopaedics. Her clinical and research interests include physical frailty and bone metabolism with a focus on prevention of functional decline and fragility fractures. The overall aim is to improve patient care and quality of life in older adults.

The Clinical Identification and Treatment of Sexually Transmitted Diseases

Marguerite Urban, MD
Associate Professor of Medicine
University of Rochester Medical Center

Presentation Date: 05/25/2012

Release Date: 06/21/2012

Course Overview

Learning Objectives

List at least three sexually transmitted diseases (STDs) that clinicians typical fail to diagnose.
Explain why clinicians fail to diagnose common STDs.
Discuss the benefits to public health of routinely screening HIV patients for other STDs.

Presenter Bio

Marguerite A. Urban, MD is Associate Professor in the Department of Medicine, Infectious Diseases at the University of Rochester and Medical Director, Monroe County Sexually Transmitted Diseases Clinic. Dr. Urban graduated from Medical College of Pennsylvania, and is certified by the American Board of Internal Medicine. Her research interest is related to sexual behavior, sexual risk reduction and sexual health. Dr. Urban is the author and co-author of numerous journal articles.

Evidence Based Medicine and HIV Prevention

Monica Sweeney, MD, MPH
Assistant Commissioner
Bureau of HIV/AIDS Prevention and Control, New York City Department of Health and Mental Hygiene

Presentation Date: 05/25/2012

Release Date: 06/21/2012

Course Overview

Learning Objectives

Describe the role of non-medical determinants in fueling the HIV/AIDS epidemic.
Explain the role of physicians, especially primary care providers, in decreasing transmission of HIV.
Discuss the role of HIV treatment as HIV prevention.

Presenter Bio

Monica Sweeney<cfif len(qPresenters.presenter_credential)>, MD, MPH</cfif>

Dr. Monica Sweeney oversees a comprehensive effort to improve HIV Prevention, Diagnosis, Care, Treatment, and Case Management. Since joining the Department of Health and Mental Hygiene HIV/AIDS Prevention and Control in 2007, she has managed the expansion of the NYC Condom campaign and the launch of the Bronx Knows HIV Testing Initiative. She has also overseen the first effort to estimate HIV incidence in New York City. Before coming to the Health Department, Dr. Sweeney served as medical director and then vice president of medical affairs at the Bedford Stuyvesant Family Health Center in Brooklyn, where she provided primary care for 18 years. Dr. Sweeney also served as a member of the Presidential Advisory Council on HIV/AIDS as president of the Kings County Medical Society, and as co-chair of the Physician Prevention Advisory Council, a project of the New York State Health Department’s AIDS Institute. She is also an assistant professor at SUNY Downstate’s School of Public Health and adjunct professor at the Sophie Davis School of Biomedical Education. Dr. Sweeney is the author of Condom Sense: A Guide to Sexual Survival in the New Millennium. She holds a medical degree from SUNY Downstate Medical Center and a master’s degree from the Mailman School of Public Health, at Columbia University.

Antiretroviral Therapy 2012: Current and Future Perspectives (Pathogenesis Driven ART)

Scott Hammer, MD
Harold C. Neu Professor of Medicine and Chief, Division of Infectious Diseases
Columbia University Medical Center/New York-Presbyterian Hospital

Presentation Date: 05/25/2012

Release Date: 06/21/2012

Course Overview

Learning Objectives

Discuss the current approach to antiretroviral therapy for HIV infection.
Explain advantages and disadvantages of regimens for initial therapy of HIV-1 infection.
Describe the approach to treatment in patients who develop drug-resistant HIV-1.
Discuss the future directions of antiretroviral therapy.

Presenter Bio

Scott Hammer<cfif len(qPresenters.presenter_credential)>, MD</cfif>

Dr. Hammer’s major investigative interest is the treatment and prevention of HIV disease. He is an investigator in the National Institutes of Health sponsored AIDS Clinical Trials Group (ACTG). Dr. Hammer is also an investigator in the National Institutes of Health sponsored HIV Vaccine Trials Network (HVTN), a multicenter organization whose mission is to develop an effective preventive HIV vaccine. He is the current protocol chair of HVTN 505, an advanced phase II study of the preventive HIV vaccine regimen developed by NIAID’s Vaccine Research Center. He is a former Chair of the AIDS Vaccine Research Working Group of the Division of AIDS, NIAID, and the Antiviral Products Advisory Committee of the Food and Drug Administration and currently serves on the Editorial Board of the New England Journal of Medicine. Dr. Hammer is a former Chair of the International AIDS Society-USA’s Antiretroviral Guidelines Panel and former Vice Chair of the World Health Organization’s Strategic and Technical Advisory Committee for HIV/AIDS. He chaired the Guidelines Development Group of the WHO’s Antiretroviral Guidelines for Resource Limited Settings in 2002, 2003 and 2006 and co-chaired the Steering Committee of the WHO’s Global HIV Drug Resistance Surveillance Program. In his role as Chief of the Division of Infectious Diseases at CUMC, he is dedicated to fellow and faculty growth and to the development of state-of-the-art infection surveillance at the institutional and regional levels to improve and protect the public health.

Eradication of HIV-1: Is a Cure Possible?

Stephen Dewhurst, PhD
Chair and Professor of Microbiology and Immunology
University of Rochester School of Medicine and Dentistry

Presentation Date: 05/25/2012

Release Date: 06/21/2012

Course Overview

Learning Objectives

Describe the cellular and anatomic reservoirs of HIV-1 infection.
Explain the medical interventions that led to Timothy Ray Brown being apparently cured of HIV-1 infection.
Outline approaches that are being used to reactivate latent HIV-1 infection, in order to purge the virus.
Explain how genetic engineering and zinc finger nucleases are being used to try to develop a cure.

Presenter Bio

Stephen Dewhurst<cfif len(qPresenters.presenter_credential)>, PhD</cfif>

Dr. Dewhurst is Dean's Professor and Chair of Microbiology & Immunology at the University of Rochester School of Medicine and Dentistry (URSMD). He received his Ph.D. from the University of Nebraska Medical Center in 1987, and performed postdoctoral training at Columbia University and at the Harvard School of Public Health, under the direction of Dr. Jim Mullins. His doctoral and postdoctoral work focussed on the pathogenesis of human and simian immunodeficiency viruses. He has been a member of the faculty at the University of Rochester since 1990, and served as Senior Associate Dean for Basic Research at the URSMD from 2007 to 2009. He has over 20 years experience as a molecular virologist, working on both RNA and DNA viruses (including HIV-1 and human herpesviruses) and is expert in the areas of viral gene transfer vectors, HIV-1 vaccine development and neuroAIDS. He has served on many NIH special emphasis and regular grant review panels and is a former Study Section Chair as well as a past (2004-2008) member of the NIH Recombinant Advisory Committee (RAC), which oversees all recombinant DNA studies in human subjects. He serves as Director of the UR's NIH-funded Development Center for AIDS Research, and also directs a NIH-funded Predoctoral training program in HIV-1 research, in addition to his own research.

Adherence to Antiretroviral Therapy Among Substance Users [CE Available]

Tanya Zangaglia, M.D.
Medical Director
Project Streetbeat

Presentation Date: 06/08/2012

Release Date: 06/08/2012

Course Overview

Learning Objectives

State that near perfect adherence (>90-95%) is the goal for HIV – infected patients.
Identify at least three factors related to adherence.
Identify three potential barriers to adherence.
State the importance of discussion of adherence & the development of antiretroviral resistance with clients.

Presenter Bio

Dr. Zangaglia is the Medical Director for Project Streetbeat as well as a Lecturer for the AIDS Education & Training Centers and Clinical Education Initiative (CEI).

HIV Testing in Dental Clinics

Karl Hoffmann, DDS
Director of Dentistry
Center for Comprehensive Care at St. Luke's Roosevelt Hospital

Presentation Date: 04/27/2012

Release Date: 04/27/2012

Course Overview

Post CROI 2012 Update

Amneris Luque, MD
Professor of Medicine, University of Rochester School of Medicine and Dentistry, and Director AIDS Center
University of Rochester Medical Center

Presentation Date: 04/12/2012

Release Date: 04/27/2012

Course Overview

Adherence and the HIV Patient

Minda Dwyer, ANP-c, AAHIVS
Adult Nurse Practitioner
Albany Medical Center

Presentation Date: 04/25/2012

Release Date: 04/25/2012

Course Overview

Smoking Cessation in the HIV Patient

Jameela Yusuff, MD
SUNY Downstate Medical Center

Presentation Date: 04/14/2010

Release Date: 04/17/2012

Course Overview

Learning Objectives

Understand the changing paradigm of HIV.
Understand data on approach and management of smoking cessation among HIV patients.
Be familiar with smoking cessation tools: 5A's, nicotine replacement.

Presenter Bio

Dr. Yusuff began working with the STAR (Special Treatment and Research) Health Center in 2006. She is board certified in internal medicine and completed an infectious disease fellowship at Beth Israel Medical Center in June 2006. She has conducted research related to predictors of STDs in an urban HIV clinic. Dr. Yusuff coordinates the hepatitis C screening and treatment in the SHC, ensuring quality of care and coordination of services for patients who are co-infected with HIV and HCV.

What’s New in HIV Drug Resistance

Daniel Kuritzkes, MD
Professor
Harvard Medical School

Presentation Date: 04/05/2012

Release Date: 04/05/2012

Course Overview

Learning Objectives

2nd generation NNRTIs.
Integrase inhibitors
CCR5 antagonists
Drug-resistant minority variants

Presenter Bio

Daniel R. Kuritzkes, MD is Professor of Medicine at Harvard Medical School and Chief of Infectious Diseases Division at Brigham and Women's Hospital. Dr. Kuritzkes also is principal investigator and chair of the AIDS Clinical Trials Group (ACTG), and associate editor for The Journal of Infectious Diseases. Dr. Kuritzkes research interest focuses on antiretroviral therapy and drug resistance. He is author of more than 48 journal articles on HIV-related topics. He received his B.S. and M.S. from Yale and his M.D. from Harvard Medical School.

HIV Diagnostics: New Technologies and Strategies

Monica Parker, PhD
Director Bloodborne Virus Laboratory
Wadsworth Center, NYSDOH

Presentation Date: 03/01/2012

Release Date: 03/01/2012

Course Overview

Learning Objectives

Review the principles of HIV diagnostic testing.
Describe new laboratory tests that aid in earlier and more accurate detection of HIV.
Present new testing strategies being proposed for HIV diagnostic.

Presenter Bio

Monica Parker, PhD is Director of the Bloodborne Viruses Laboratory, and Faculty at Wadsworth Center School of Laboratory Sciences. She received her Ph.D. from University at Albany School of Public Health and her post-doctoral training from Wadsworth Center, NYSDOH. The Bloodborne Viruses Laboratory serves as the NY state public health reference laboratory for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) testing. Dr. Parker's research interests focus on new methods and strategies for improving diagnosis and clinical management of HIV and HCV infections, the development of methods which are not commercially available and the optimization of testing strategies for early detection of HIV infection.

The Changing Spectrum of HIV-Associated Malignancies

Alvaro Carrascal, MD, MPH
Senior Vice President, Cancer Control
American Cancer Society

Presentation Date: 02/09/2012

Release Date: 02/09/2012

Course Overview

HIV/AIDS Confidentiality Law Overview [CE Available]

Sally Friedman, Esq.
Legal Director
Legal Action Center

Presentation Date: 06/19/2012

Release Date: 01/26/2012

Course Overview

Learning Objectives

State the basic requirements of the New York State HIV confidentiality law.
List the main exceptions to the HIV confidentiality law’s non-disclosure rule.
Complete an HIV release form.
Describe the legal consequences for violating the HIV confidentiality law.

Presenter Bio

Ms. Friedman directs the Center’s Legal Department, which serves over 2,500 clients annually and provides trainings and technical assistance for hundreds of health and social service program serving LAC’s constituency. Since joining the Legal Action Center in October of 1993, Sally Friedman has prosecuted cases involving the breach of HIV confidentiality and discrimination on basis of HIV status, criminal record, and drug or alcohol history. She has also advised and trained hundreds of organizations across the country on privacy and anti-discrimination laws protecting individuals with HIV, criminal records, and alcohol/drug histories. Ms. Friedman has authored numerous publications and produced video/DVD and online trainings on these topics. She is a graduate of Brown University and New York University Law School.

Street Drugs & HIV [CE Available]

Sharon Stancliff, MD
Medical Director
Harm Reduction Coalition

Presentation Date: 12/08/2011

Release Date: 01/24/2012

Course Overview

Learning Objectives

Describe the interaction of substance use and HIV medications.
Be familiar with documented risks of substance use.
Understand effects of Marijuana & Benozodiazepines.
Understand possible treatment interventions.

Presenter Bio

Sharon Stancliff is the Medical Director of the Harm Reduction Coalition where she oversees SKOOP, an overdose prevention project, and runs a buprenorphine demonstration project. She is also a medical consultant for the AIDS Institute, New York State Department of Health. She has worked with drug users in methadone maintenance, primary care and at syringe exchanges and has published articles related to harm reduction and drug treatment.

HIV Prevention & Care for LGBT Youth - A Conference for Medical Providers

Honor Thy Anus. Anal Health in Young MSM: Unraveling the Squeamishness

Jeff Huyett, NP
Clinical Director of Anal Health
Callen-Lorde Community Health Center, New York, NY

Presentation Date: 01/19/2012

Release Date: 01/19/2012

STD Screening in Young MSMs

Alwyn Cohall, MD
Director, Harlem Health Promotion Center and Project STAY
Mailman School of Public Health, Columbia University, New York, NY

Presentation Date: 01/19/2012

Release Date: 01/19/2012

Course Overview

Mental Health Care for LGBT Youth living with HIV/AIDS

Warren Ng, MD
Assistant Clinical Professor of Psychiatry
Columbia University

Presentation Date: 01/19/2012

Release Date: 01/19/2012

Course Overview

Community-based Strategies: HIV Prevention Strategies for YMSM

Michael Camacho, MPH
Outreach Program Manager, Adolescent AIDS Program
Montefiore Medical Center, Bronx, NY
Michael Roberson
Consultant

Presentation Date: 01/19/2012

Release Date: 01/19/2012

HIV Prevention Strategies in LGBT Youth: Clinical Based Approach

Sanjiv Shah, MD, MPH
North Shore University Hospital

Presentation Date: 01/19/2012

Release Date: 01/19/2012

Course Overview

Hepatitis C and HIV

Peter Mariuz, MD
Associate Professor of Medicine
University of Rochester Medical Center

Presentation Date: 12/23/2011

Release Date: 12/23/2011

Course Overview

Health Literacy- Working Together

Erica Dobson, PharmD, BCPS, AAHIVE
University of Rochester Medical Centerr

Presentation Date: 12/20/2011

Release Date: 12/20/2011

Course Overview

How to Talk to Patients About Their Sexual and Personal Lives

Susan Hulse, RPA-C
University of Rochester Medical Center

Presentation Date: 12/12/2011

Release Date: 12/12/2011

HIV and Aging

David Herman, MD, AAHIVE
Assistant Professor of Medicine
Albany Medical College

Presentation Date: 12/01/2011

Release Date: 12/01/2011

HIV and Sexually Transmitted Infections [CE Available]

Marguerite Urban, MD
Associate Professor of Medicine
University of Rochester Medical Center

Presentation Date: 10/04/2011

Release Date: 10/27/2011

Course Overview

Learning Objectives

Describe the epidemiologic associations between HIV and other sexually transmitted infections (STIs).
Describe the clinical manifestations of syphilis and how they may be altered in the setting of co-infection with HIV.
Describe the clinical manifestations of gonorrhea and chlamydia.

Presenter Bio

HIV and Cardiovascular Disease

Todd Ellerin, MD
Director, Infectious Diseases and Vice Chairman
Department of Medicine, South Shore Hospital and Brigham and Women's Hospital, Harvard Medical School

Presentation Date: 10/06/2011

Release Date: 10/06/2011

Course Overview

Kidney and Liver Transplantation in People with HIV

Christopher Barry, MD, PhD, FACS
Associate Professor
University of Rochester Medical Center

Presentation Date: 10/03/2011

Release Date: 10/03/2011

Course Overview

Aspects of HIV Epidemiology

Monica Barbosu, MD, PhD
University of Rochester Medical Center

Presentation Date: 09/13/2011

Release Date: 09/13/2011

HCV Treatment Update

Peter Ells, MD
Associate Professor of Clinical Medicine
Division of Gastroenterology-Hepatology, Albany Medical Center

Presentation Date: 09/01/2011

Release Date: 09/01/2011

Course Overview

Learning Objectives

Understand the epidemiology and prevention of Hepatitis C.
Evaluate the current standards of care for the Hepatitis C infected patient.
Identify new drug treatment regimens available for HCV and how they should be utilized in a patient a patient co-infected with HIV to obtain a virologic response.

Presenter Bio

Dr. Ells is Associate Professor of Clinical Medicine in the Division of Gastroenterology-Hepatology, Albany Medical Center. Dr. Ells’ special interest and expertise is in treating patients with hepatitis B and C, and hemochromatosis.

Preconception and Prenatal Care for the HIV Positive Woman

Joseph McGowan, MD, FACP
Medical Director
Center for AIDS Research and Treatment, North Shore University Hospital

Presentation Date: 04/14/2010

Release Date: 08/31/2011

Course Overview

Learning Objectives

Describe HIV epidemiology in HIV Mother to Child Transmission (MTCT).
Describe key components of preconception care.
Review HIV care during pregnancy and post partum.
Recognize the symptoms of acute HIV.
Discuss the importance of continuity of care for the pregnant woman with HIV.

Presenter Bio

Dr. McGowan is an Associate Professor of Medicine at Albert Einstein College of Medicine and Medical Director for Center for AIDS Research and Treatment at North Shore University Hospital. Dr. McGowan has been involved in HIV research for over a decade, and has served as principal investigator for over two dozen clinical trials. He is the author of more than 30 journal articles and has contributed to several books on infectious disease. Dr. McGowan’s primary research interests are HIV in people over 50 and the treatment of pregnant women with HIV. Dr. Joseph McGowan disclosed that he has received funds for research from Gilead, Tibotec, and VIIV.

Statewide Medicaid Managed Care for People Living with HIV/AIDS: New Developments Outside of New York City

Ira Feldman
Deputy Director for Medicaid Policy and Programs
New York State AIDS Institute

Presentation Date: 06/16/2011

Release Date: 06/16/2011

HIV Drug Resistance Testing in the Golden Age of Antiretroviral Therapy [CE Available]

Athe Tsibiris, MD, MS
Assistant Professor of Medicine
Harvard Medical School

Presentation Date: 06/14/2011

Release Date: 06/14/2011

Co-sponsor:

Course Overview

Learning Objectives

Identify rates of transmitted HIV drug resistance worldwide
Determine the optimal timing of HIV drug resistance testing
Discuss the changing mutation patterns of HIV drug resistance
Understand the relationship between HIV drug resistance and class-sparing regimens.

Presenter Bio

Athe Tsibris, MD, is an Assistant Professor of Medicine at Harvard Medical School, and Assistant in Medicine at the Massachusetts General Hospital. Dr. Tsibris’s research currently focuses on the characterization of HIV-1 resistance to CCR5 antagonists, and the use of ultra-deep sequencing to demonstrate dynamic HIV-1 escape from CCR5 inhibition in vivo. In addition to his translational, bench-side research, Dr. Tsibris is committed to integrating novel lab findings of HIV drug resistance to improve patient care worldwide, while continuing to be involved in clinical care and teaching.

Is There Ongoing Virus Replication During Apparently Suppressive ART? [CE Available]

Teresa Evering, MD
Associate Attending Physician
Rockefeller University Hospital
Martin Markowitz, MD
Aaron Diamond Professor
The Rockefeller University

Presentation Date: 06/14/2011

Release Date: 06/14/2011

Co-sponsor:

Course Overview

Learning Objectives

Discuss the effects of HIV-1 on the GI tract and immune reconstitution after cART is given.
Know whether persistent CD4 depletion and immune activation in the lamina propria of the lower GI tract is due to ongoing virus replication.
Appreciate whether 5-drug ART begun during acute and early infection results in virologic and immunologic benefit when compared to standard 3-drug ART?

Presenter Bio

Teresa Evering, MD, is an Associate Attending Physician at the Rockefeller University Hospital and Research Scientist at the ADARC, mentored by Dr. David Ho and Clinical Director of ADARC, Dr. Martin Markowitz. Dr. Evering's research has focused on questions surrounding the potential for ongoing HIV replication during suppressive highly active antiretroviral therapy, and her current work focuses primarily on the central nervous system, an important sanctuary site for HIV-1.

Presenter Bio

Martin Markowitz, MD, is Clinical Director and Staff Investigator of the Aaron Diamond AIDS Research Center (ADARC) and an Aaron Diamond Professor at The Rockefeller University in New York City. Dr. Markowitz is widely known for his research in acute and early HIV infection, HIV pathogenesis, and the development of new agents to treat HIV-1 infection.

Implementing a Successful HIV Testing Program in Emergency Department Setting

Daniel Egan, MD, FACEP
Associate Program Director
St. Luke's Roosevelt Hospital

Presentation Date: 06/07/2011

Release Date: 06/07/2011

Course Overview

Overview of the revised HIV Testing Law in New York State: Implications for your clinic setting and practice

Paul Galatowitsch, PhD
Director HIV/AIDS Education & Training
St. Luke’s Roosevelt Hospital

Presentation Date: 06/07/2011

Release Date: 06/07/2011

21th HIV/AIDS Clinical Conference:The Hope and the Challenges of Restoring Health

Antiretroviral Therapy 2011: The State of the Art

Calvin Cohen, MD, MSc
Research Director for the Community Research Initiative of New England and Harvard Vanguard Medical Associates
Harvard Medical School

Presentation Date: 05/20/2011

Release Date: 05/20/2011

Course Overview

Learning Objectives

Discuss the current approach to antiretroviral therapy for HIV infection.
Explain advantages and disadvantages of regimens for initial therapy of HIV-1 infection.
Describe the approach to treatment in patients who develop drug-resistant HIV-1.

Presenter Bio

Calvin Cohen<cfif len(qPresenters.presenter_credential)>, MD, MSc</cfif>

Calvin J. Cohen, MD, MSc is the Research Director of both Community Research Initiative of New England and Harvard Vanguard Medical Associates, and a Clinical Instructor at Harvard Medical School. Dr. Cohen's research focuses on HIV antiviral trials. He is a member of the Scientific Steering Committee of the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), an NIH-supported International network of clinician-researchers. He received the Outstanding Physician's Award by Harvard Vanguard Medical Associates, the Ebert Teaching award by Harvard Pilgrim Health Care, and the Community Recognition Award from the AIDS Action Committee of Massachusetts.

Management of Personality Pathology in Chronic HIV Care: Maintaining both Provider and Patient Mental Health

Shuki Cohen, PhD, MSc
Assistant Clinical Professor of Psychiatry
Yale Medical School

Presentation Date: 05/20/2011

Release Date: 05/20/2011

Course Overview

Learning Objectives

Utilize current conceptualizations of personality disorders, especially those typical to chronic HIV care.
Recognize the effects of sub-clinical personality pathologies in treatments such as therapeutic alliance and medication adherence.
Recognize their patients’ personality turmoil while maintaining their own emotional balance and prevent both patient drop out and provider burnout.

Presenter Bio

Dr. Cohen is Assistant Clinical Professor of Psychiatry at Yale Medical School and Assistant Professor of Clinical Psychology, John Jay College, New York. His main interests are in experimental psychopathology, looking at gender differences in the unconscious thinking processes that underlie depression, anxiety and anger and violence. Some of his current research projects concern implicit gender identity, gender identity threat and their relationship with insecurities, anxiety and aggression.

Cross-cultural Issues and Cultural Proficiency in Psychiatric Diagnosis and Treatment

Prantik Saha, MD, MPH
Assistant Clinical Professor
Columbia University Medical Center

Presentation Date: 05/20/2011

Release Date: 05/20/2011

Course Overview

Learning Objectives

Be cognizant of racial, ethnic and other forms of disparities in health care, especially with regards to HIV/AIDS.
Understand the relationship between provider bias/stereotyping and its contribution to disparities.
Utilize an approach to communication skills in which we can minimize bias and develop proficiency in providing care to different cultures and communities.

Presenter Bio

Prantik Saha, MD, MPH is an Assistant Clinical Professor of Pediatrics, Columbia University Medical Center, New York, and is a pediatric primary care provider for largely underserved urban immigrant communities in upper Manhattan. He is co-director of the Daniel Noyes Brown Primary Care Scholars Program at the Columbia University College of Physicians and Surgeons. Dr. Saha is also a member of the Community Advisory Board of SAHI (South Asian Health Initiative) and NPA-NY (National Physicians Alliance - New York).

Motivational Interviewing (MI) in Primary Care Settings

Prantik Saha, MD, MPH
Assistant Clinical Professor
Columbia University Medical Center

Presentation Date: 05/20/2011

Release Date: 05/20/2011

Course Overview

Learning Objectives

Understand the philosophy and spirit underlying motivational interviewing (MI).
Be cognizant of the latest evidence of MI and its effectiveness in behavior change, particularly with regards to HIV/AIDS.
Understand the utility of specific techniques often used in MI, such as importance/confidence scales.

Presenter Bio

Dealing with Domestic Violence - The NYS Approach

Sujata Warrier, PhD
NYS Office for the Prevention of Domestic Violence

Presentation Date: 05/20/2011

Release Date: 05/20/2011

Course Overview

Eradicating Mother-to-Child Transmission of HIV in New York State

Rodney Wright, MD, MS
Director of HIV Program, and Assistant Professor
Albert Einstein College of Medicine, Yeshiva University

Presentation Date: 05/20/2011

Release Date: 05/20/2011

Course Overview

Antiretroviral Management of HIV-Associated Neurocognitive Disorders [CE Available]

Scott Letendre, MD
Associate Professor of Medicine
University of California, San Diego

Presentation Date: 05/17/2011

Release Date: 05/17/2011

Co-sponsor:

Course Overview

Learning Objectives

Summarize background data on differences between antiretroviral drugs in distribution into the CNS.
Review the approach to estimating the distribution of antiretroviral regimens into the CNS.
Review results of studies that have compared estimates of antiretroviral regimens to CNS outcomes, such as HIV RNA levels in cerebrospinal fluid or neurocognitive impairment.
Suggest an approach to management of clinical patients for prevention and management of HAND.

Presenter Bio

Scott Letendre, M.D., is an Associate Professor of Medicine in the Department of Medicine, Division of Infectious Diseases, at the University of California, San Diego. Dr. Letendre's research, performed primarily at UCSD's HIV Neurobehavioral Research Center, focuses on the impact on the brain of chronic infections, primarily HIV and HCV, and their treatment. He is also an active investigator in the UCSD unit of the AIDS Clinical Trials Group (ACTG), and is currently a member of both the national ACTG Neurology Subcommittee and the ACTG Dementia Focus Group.

Epidemiology and Clinical Approach to HIV-associated CNS Disorders [CE Available]

David Simpson, MD, FRCP, FAAN
Professor of Neurology
Mount Sinai Medical Center

Presentation Date: 05/17/2011

Release Date: 05/17/2011

Co-sponsor:

Course Overview

Learning Objectives

Discuss the prevalence of neurological complications of HIV infection, with a focus on HIV neurocognitive disorders (HAND).
Understand the clinical approach and differential diagnosis of HIV-associated central nervous system (CNS) disorders.
Use screening and examination tools to diagnose HIV-associated CNS disorders.

Presenter Bio

David M. Simpson, MD, FRCP, FAA, is Professor of Neurology at Mount Sinai School of Medicine, Director of the Clinical Neurophysiology Laboratories, and Director of the Neuro-AIDS Program at Mount Sinai Medical Center in New York City. An author of 234 original publications and book chapters, Dr. Simpson is the principal investigator for many studies, including studies for the treatment of painful peripheral neuropathy. Dr. Simpson is a member of the American Neurological Association and the American Pain Society and is a Fellow of the American Academy of Neurology, the American Academy of Neuromuscular and Electrodiagnostic Medicine, and the Royal College of Physicians. He is on the editorial boards of AIDS Patient Care and Current HIV/AIDS Reports.

Identifying Adherence Barriers, Management of Antiretroviral Side Effects and Drug-Drug Interaction Update

Cara Felton, PharmD, AAHIVE
Reasearch Assistant Proffessor
University of Buffalo, School of Pharmacy and Pharmaceutical Sciences

Presentation Date: 05/06/2011

Release Date: 05/06/2011

Course Overview

Learning Objectives

Describe potential adherence barriers to antiretroviral therapy.
Identify strategies to overcome those barriers.
Describe adverse effects related to antiretroviral medications.
Identify strategies to manage those adverse effects.
Describe common mechanisms of ARV drug-drug interactions.
Identify medications that interact, or potentially interact, with ARVs.

Presenter Bio

Cara M. Felton, PharmD, is a Research Assistant Professor at University of Buffalo, School of Pharmacy and Pharmaceutical Sciences. She is involved in the Medication Management Research Network that was developed by the New York State Center of Excellence in Bioinformatics and Life Sciences (CoE) and the UB School of Pharmacy and Pharmaceutical Sciences. The purpose of this network is to establish a healthcare informatics infrastructure that conducts medication management research.

New Challenges in HCV Treatment Adherence: Applying Lessons Learned from HIV Antiretroviral Treatment Adherence Research

Jeffrey Weiss, PhD, MS
Assistant Professor of Medicine and Assistant Professor of Psychiatry
Mount Sinai School of Medicine

Presentation Date: 04/14/2011

Release Date: 04/14/2011

Course Overview

CROI 2011 Update

Amneris Luque, MD
Professor of Medicine, University of Rochester School of Medicine and Dentistry, and Director AIDS Center
University of Rochester Medical Center

Presentation Date: 03/31/2011

Release Date: 03/31/2011

Course Overview

Antiretroviral Chemoprophylaxis [CE Available]

Kenneth Mayer, MD
Professor of Medicine and Community Health
Brown University

Presentation Date: 03/15/2011

Release Date: 03/15/2011

Co-sponsor:

Course Overview

Learning Objectives

Understand how oral antiretroviral agents may be used for pre- and post-exposure prophylaxis.
Understand how topical antiretroviral agents may be used as microbicides to prevent HIV transmission.
Understand the recent results of the CAPRISA 004 and iPrEx efficacy trials, and learn about upcoming chemoprophylaxis trials, and when their results will be known.
Learn about the possibility of using novel antiretroviral agents for chemoprophylaxis.

Presenter Bio

Kenneth Mayer, MD, is Professor of Medicine and Community Health at Brown University, Director of the Brown University AIDS Program, and Attending Physician in the Infectious Diseases Division of the Miriam Hospital in Providence, Rhode Island; and Medical Research Director at Boston's Fenway Community Health Center, where (since 1983) he has conducted studies of HIV's natural history and transmission. He has co-authored over 400 articles, chapters and other publications on AIDS and related infectious disease topics, and is a frequent lecturer and presenter at national and international conferences and symposia.

Current Controversies in Antiretroviral Therapy [CE Available]

Roy Gulick, MD, MPH
Professor of Medicine and Chief of the Division of Infectious Diseases
Weill Medical College of Cornell University in New York City

Presentation Date: 03/15/2011

Release Date: 03/15/2011

Co-sponsor:

Course Overview

Learning Objectives

Be aware of newer antiretroviral agents.
Discuss the latest data on strategies for starting antiretroviral therapy and what to start with.
Discuss the latest data on when to change antiretroviral therapy and what to change to.

Presenter Bio

Prevention with Positives: Young MSM

Sanjiv Shah, MD, MPH
North Shore University Hospital

Presentation Date: 02/18/2011

Release Date: 02/18/2011

Course Overview

Domestic Violence

Gwen Wright
Director of Human Services and Prevention
New York State Office for the Prevention of Domestic Violence

Presentation Date: 02/07/2011

Release Date: 02/07/2011

Course Overview

Learning Objectives

Understand the prevalence of domestic violence in NYS.
Understand the implication of domestic violence on positive health outcomes.
Understand the complexities of HIV/AIDS treatment when domestic violence is implicated.
Become familiar the resources available for victims of domestic violence.

Presenter Bio

Gwen J. Wright is the Director of Human Services and Prevention for the NYS Office for the Prevention of Domestic Violence. Her work is dedicated to improve New York State’s response to and prevention of domestic violence, in order to increase people’s safety in their family and intimate relationships. She works with both survivors and helpers on the problem of domestic violence, safety planning, and ways to get help from domestic violence services, the police, and the courts.

HIV Viral Load: New Opportunities & Advances in Technology [CE Available]

William Valenti, MD
Clinical Associate Professor of Medicine at the University of Rochester School of Medicine and Dentistry
AIDS Care

Presentation Date: 01/18/2011

Release Date: 01/18/2011

Co-sponsor:

Course Overview

Learning Objectives

Understand the clinical significance of low-level viremia.
Understand the role of Community Viral Load in HIV care.
Understand the role of HIV treatment and undetectable viral load as prevention tools.
Recognize advances in viral load technologies that support contemporary HIV treatment.

Presenter Bio

Bill Valenti, MD, is an internist/ infectious diseases specialist and a native of Rochester, NY. He has been doing HIV Medicine since the early 1980s, and is the Founding Medical Director of Community Health Network (now AIDS Care), a not-for-profit organization for people with HIV/AIDS, where he continues to see patients. Dr. Valenti is Clinical Associate Professor of Medicine at the University of Rochester School of Medicine and Dentistry, and is chair of the Infectious Diseases Subcommittee of Medical Society of the State of New York (MSSNY).

HIV and Oral Health Care [CE Available]

Amneris Luque, MD
Professor of Medicine, University of Rochester School of Medicine and Dentistry, and Director AIDS Center
University of Rochester Medical Center

Presentation Date: 01/05/2011

Release Date: 01/05/2011

Course Overview

Learning Objectives

Describe the signs and symptoms of HIV infection
Explain antiretroviral treatment for HIV infection
List pretreatment considerations for HIV/AIDS patients undergoing dental procedures.

Presenter Bio

Amneris E. Luque, MD is Professor of Medicine, at the University of Rochester School of Medicine and Dentistry, and the Director of the AIDS Center at the University of Rochester Medical Center. As an HIV/AIDS specialist Dr. Luque is devoted to both HIV clinical care and clinical education. Dr. Luque is also the Medical Director of the NYSDOH AIDS Institute's HIV Clinical Education Initiative (CEI) in the Rochester – Finger Lakes area, and the Medical Director of the Technology Center, NYSDOH AI. She served as the Chair of the Committee for the Care of Women with HIV Infection, Chair of the NYSDOH AIDS Institute's Medical Care Criteria Committee (MCCC). Dr. Luque oversees the Quality Improvement Program at the University of Rochester Medical Center.

HIV Medication Errors [CE Available]

John Faragon, PharmD, BCPS, AAHIVE
NY/NJ AETC Regional Pharmacy Director
Albany Medical Center

Presentation Date: 12/21/2010

Release Date: 12/21/2010

Course Overview

Learning Objectives

Discuss background data on medication errors in the HIV infected population.
Review common types and causes of medication errors that occur in the HIV population.
Using patient cases, provide real life examples from the hospital and retail settings that describe HIV medication errors.
Provide strategies for preventing medication errors in the HIV infected population.

Presenter Bio

Clinical Management of Alcohol Use & Abuse in HIV-Infected Patients [CE Available]

Thomas Schmidt, PhD, CASAC
Clinic Administrator
Suffolk County Division of Community Mental Hygiene

Presentation Date: 12/08/2009

Release Date: 12/17/2010

Course Overview

Learning Objectives

Recognize the importance of alcohol screening for HIV infected patients.
Identify at least three of the areas alcohol use/abuse impacts on clinical management of HIV.
Define at-risk drinking, alcohol abuse, alcohol dependence, binge drinking and a "standard drink".
State primary role, with regard to alcohol, of the clinician in the management of the patient who abuses/dependent on alcohol.

Presenter Bio

Thomas Schmidt is the Clinic Administrator of the Suffolk County Division of Community Mental Hygiene. He has been treatment provider and trainer of substance abuse treatment professionals in downstate New York for almost 30 years. His clinical experience is in the medication-assisted treatment of opioid dependence. Included in this experience was an eight year period overseeing the provision of primary medical care and case management services to HIV-infected individuals enrolled in methadone treatment programs located in Suffolk County.

Toward a Cure for HIV: Are We There Yet? [CE Available]

Tae-Wook Chun, PhD
Associate Scientist
National Institute of Allergy and Infectious Diseases

Presentation Date: 11/16/2010

Release Date: 11/16/2010

Co-sponsor:

Course Overview

Learning Objectives

Understand the evolution of HIV reservoir research.
Explain the impact of antiretroviral therapy on HIV reservoirs.
Discuss the mechanisms of HIV persistence in infected individuals receiving antiretroviral therapy.
Examine the feasibility of eradication of HIV in infected individuals receiving antiretroviral therapy.

Presenter Bio

Tae-Wook Chun received his PhD degree at the Johns Hopkins University School of Medicine in 1997. While working with Dr. Robert Siliciano at Johns Hopkins, he identified and characterized latently infected, resting CD4+ T cells in HIV-infected individuals. He conducted his postdoctoral work in Dr. Anthony Fauci's laboratory at National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH). He is currently an Associate Scientist at NIH and continues to study the role of viral reservoirs in the pathogenesis of HIV in infected individuals receiving effective antiretroviral therapy.

Unraveling the Genetic Basis of HIV Control [CE Available]

Bruce Walker, MD
Professor of Medicine
Harvard Medical School

Presentation Date: 11/16/2010

Release Date: 11/16/2010

Co-sponsor:

Course Overview

Learning Objectives

Better appreciate the use of genome-wide association scans to understand human disease.
Describe the genetic basis for control and lack of control of HIV.
Discuss the implications of genetic studies for vaccine design.
Understand the effects of immune selection pressure on viral fitness.

Presenter Bio

Bruce Walker, MD, is Professor of Medicine at Harvard Medical School, a Howard Hughes Medical Institute Investigator, Director of the newly formed Ragon Institute of MGH, MIT and Harvard, and Adjunct Professor at the Nelson Mandela School of Medicine in Durban, South Africa. His research focuses on cellular immune responses in chronic viral infections, with a particular focus on HIV. He leads an international translational clinical and basic science research effort to understand how some rare people who are infected with HIV, but have never been treated, can fight the virus with their immune system.

New Drugs and Strategies in the Treatment of HIV Disease [CE Available]

Calvin Cohen, MD, MSc
Research Director for the Community Research Initiative of New England and Harvard Vanguard Medical Associates
Harvard Medical School

Presentation Date: 09/21/2010

Release Date: 09/21/2010

Co-sponsor:

Course Overview

Learning Objectives

Review data on drugs in phase 3 of development for the treatment of HIV disease.
Describe new strategies for combining antiretroviral agents.
Discuss data on 2-drug combinations and induction/maintenance in the treatment of HIV disease.

Presenter Bio

Vitamin D Deficiency in the HIV-infected Patient [CE Available]

Todd Brown, MD, PhD
Associate Professor of Medicine
Johns Hopkins University

Presentation Date: 09/21/2010

Release Date: 09/21/2010

Co-sponsor:

Course Overview

Learning Objectives

Describe the action of vitamin D and the potential consequences of vitamin D deficiency.
Define the factors associated with abnormal vitamin D metabolism in the HIV-infected patient.
Discuss current recommendations for screening & treatment of vitamin D deficiency in HIV-infected patients.

Presenter Bio

Prevention for Positives and Negatives

Ann Weisbeck, MS, FNP
Nurse Practitioner
University of Rochester Medical Center

Presentation Date: 08/08/2010

Release Date: 08/08/2010

Course Overview

Learning Objectives

Explain the importance of discussing the prevention of HIV transmission with both HIV positive and HIV negative patients.
Identify the various factors that influence an individual’s likelihood of transmitting or acquiring HIV.
Demonstrate the rationale for making HIV testing a routine part of medical care, and understand how such testing can impact public health.
Define the counseling and behavioral interventions that health care providers can use to help their patients with HIV related behavior change.

Presenter Bio

Characterization of an Epidemic of Acute Hepatitis C Infection in HIV-positive MSM in New York City

Daniel Fierer, MD
Assistant Professor Infectious Disease
Mount Sinai School of Medicine

Presentation Date: 06/15/2010

Release Date: 05/18/2010

Co-sponsor:

Course Overview

Learning Objectives

Demonstrate an understanding of the ongoing epidemic of acute and early HCV in HIV-positive MSM.
Understand the variables that lead to increased risk of HCV infection in HIV-positive MSM.
Diagnose acute and early HCV in HIV-positive MSM.
Understand the virologic, unique histologic and clinical course of acute and early HCV in HIV-positive MSM.

Presenter Bio

Daniel S. Fierer, MD trained at the National Institutes of Health, specializing in the molecular virology of Herpesvirus infections, and was recruited to the Mount Sinai School of Medicine, working in the field of HIV pathogenesis. In 2006, he and his colleagues at Mount Sinai recognized the presence of an epidemic of hepatitis C infection among HIV-infected men-who-have-sex-with-men in New York City. The main focus of his current work is the characterization of this epidemic and the treatment of the affected patients.

Quadrivalent HPV vaccine in HIV-positive and HIV-negative men who have sex with men

Stephen Goldstone, MD, FACS
Assistant Clinical Professor of Surgery
Mount Sinai School of Medicine

Presentation Date: 05/18/2010

Release Date: 05/18/2010

Co-sponsor:

Course Overview

Learning Objectives

Understand the efficacy of quadrivalent HPV vaccine in preventing anal intraepithelial neoplasia in men who have sex with men.
Understand the efficacy of quadrivalent HPV vaccine at preventing anal HPV infection in men who have sex with men.
Discuss the safety profile of quadrivalent HPV vaccine in HIV-positive men.

Presenter Bio

Diagnostic assessment and treatment recommendations

Warren Ng, MD
Assistant Clinical Professor of Psychiatry
Columbia University

Presentation Date: 04/26/2010

Release Date: 04/26/2010

Course Overview

Learning Objectives

Review clinical psychiatric and developmental disorders for youth with HIV.
Identify the effects of HIV disease on behavior and cognitive functioning.
Review common psychiatric disorders of HIV youth.
ADHD diagnosis and treatment strategies.

Presenter Bio

Dr. Ng is a child, adolescent, and adult psychiatrist with an interest in HIV, public psychiatry, and family issues. He is the Director of the Special Needs Clinic, New York Presbyterian Hospital- Columbia University Medical Center, and the Co-Director of the Family Care Center at Harlem Hospital. He is also the staff psychiatrist for Incarnation Children’s Center and Project Stay. Dr. Ng is on the guidelines committee of the AIDS Institute at the New York State Department of Health. Dr. Ng has been the past president of the New York Council on Child and Adolescent Psychiatry and a delegate to the American Academy of Child and Adolescent Psychiatry.

Psychiatric Evaluations for Persons Living with HIV/AIDS

Warren Ng, MD
Assistant Clinical Professor of Psychiatry
Columbia University

Presentation Date: 04/26/2010

Release Date: 04/26/2010

Course Overview

Learning Objectives

Discuss the mental health issues that people living with HIV/AIDS are facing.
Present the CDQ Screener for mental illness and substance abuse.
Discuss techniques PCP use in the diagnoses of psychiatric disorders in HIV infected patients.

Presenter Bio

When the First Treatment Fails: Choosing a Second Antiretroviral Regimen in HIV Disease

Timothy Wilkin, MD, MPH
Assistant Professor of Medicine
Weill Medical College of Cornell University in New York City

Presentation Date: 06/15/2010

Release Date: 04/20/2010

Co-sponsor:

Course Overview

Learning Objectives

Understand the clinical and laboratory distinctions between virologic, immunologic, and clinical failure of a first-line regimen.
Evaluate and determine the necessary criteria for developing a second antiretroviral regimen.
Integrate newer antiretroviral agents into second-line regimen options.

Presenter Bio

Timothy Wilkin, MD, MPH is an investigator with the Cornell HIV Clinical Trials Unit and an Assistant Professor of Medicine at Weill Medical College of Cornell University in New York City. His research interests include the epidemiology, diagnosis, management and prevention of human papillomavirus infection and anal dysplasia in HIV-infected adults, and the epidemiology coreceptor tropism in HIV-infected populations. He is also an investigator with the AIDS Clinical Trial Group and the AIDS Malignancy Consortium.

Antiretroviral Therapy for HIV-infected Individuals: An HIV Transmission Prevention Strategy?

Wafaa El-Sadr, MD, MPH
Professor of Medicine and Epidemiology
Columbia University

Presentation Date: 04/20/2010

Release Date: 04/20/2010

Co-sponsor:

Course Overview

Learning Objectives

Understand the relation of HIV viral load to transmission risk, and the potential role of antiretroviral suppression of viral replication as a transmission-prevention measure.
Describe available evidence supporting the role of antiretroviral therapy of HIV-infected individuals in preventing the sexual transmission of HIV to uninfected partners.
Know of planned research studies to address the question of whether treatment of HIV-infected individuals can prevent further transmission in communities at risk.

Presenter Bio

Wafaa El-Sadr, MD is Professor of Medicine and Epidemiology at Columbia University, the Director of the International Center for AIDS Care and Treatment Programs (ICAP) and the Director of the Global Health Initiative at Columbia University's Mailman School of Public Health. As chief of the Division of Infectious Diseases at Harlem Hospital Center in New York City, she fostered the development of a comprehensive HIV/AIDS and tuberculosis program that applies a family-focused approach, uses multidisciplinary teams, and engages community members. ICAP, the Center she founded and currently directs, works in 14 countries in sub-Saharan Africa serving over one million individuals living with HIV. Her work has advanced the concepts of health systems confronting major health threats faced by communities around the world.

Initiating Antiretroviral Therapy in HIV Treatment-naive Individuals

Timothy Wilkin, MD, MPH
Assistant Professor of Medicine
Weill Medical College of Cornell University in New York City

Presentation Date: 04/20/2010

Release Date: 04/20/2010

Co-sponsor:

Course Overview

Ask the Psychiatrist: Discussion About Clients with Anxiety Disorders Living with HIV/AIDS

Warren Ng, MD
Assistant Clinical Professor of Psychiatry
Columbia University

Presentation Date: 03/29/2010

Release Date: 03/29/2010

Course Overview

Antiretroviral Pre-exposure Prophylaxis (PrEP) for HIV Prevention: Efficacy Trials and Planning for Results

Connie Celum, MD, MPH
Professor of Global Health and Medicine
University of Washington

Presentation Date: 03/23/2010

Release Date: 03/23/2010

Co-sponsor:

Course Overview

Learning Objectives

Summarize the rationale, design and status of ongoing efficacy trials of antiretroviral pre-exposure prophylaxis (PrEP) for HIV prevention.
Discuss considerations for implementation if PrEP is shown to be efficacious and safe.
Discuss remaining research questions about PrEP.

Presenter Bio

Connie Celum, MD is Professor of Global Health and Medicine at University of Washington and Director of the International Clinical Research Center in the Dept of Global Health. She received her medical school and internal medicine residency training at University of California San Francisco and infectious disease training and epidemiology training at University of Washington. Her research currently focuses on clinical trials of biomedical HIV prevention and combination HIV prevention strategies with the objective to find effective strategies to reduce HIV acquisition and transmission.

Current STD Findings in NYC and Implications for Diagnosis and Treatment in HIV Primary Care

Eunmee Chun, MD, MPH
Assistant Medical Director
Region II STD/HIV Prevention Training Center (PTC)

Presentation Date: 03/23/2010

Release Date: 03/23/2010

Co-sponsor:

Course Overview

Learning Objectives

Describe the epidemiology of STDs diagnosed among HIV positive patients in the Bureau of STD (BSTD) clinics in New York City.
Discuss Bureau of STD data from acute HIV screening using pooled HIV NAAT testing.
Describe the burden of primary and secondary syphilis, lymphogranuloma venereum, gonorrhea and Chlamydia infections in New York City.
Understand the diagnosis and treatment of syphilis, LGV, gonorrhea, Chlamydia and herpes simplex in the setting of HIV treatment and prevention, as well as the legal requirements and mechanisms for reporting STDs in New York City.

Presenter Bio

Dr. Chun is the Assistant Medical Director of the Region II STD/HIV Prevention Training Center (PTC), a CDC-funded provider education grant at the NYC DOHMH Bureau of STD Prevention and Control. She was formerly an associate medical director in the Office of the Medical Director at the NYS DOH AIDS Institute. She is board-certified in Internal Medicine and previously practiced primary care at a community-based adult medicine clinic.

NYSDOH Immune Reconstitution Inflammatory Syndrome (IRIS) Guidelines: A Case Presentation

Amneris Luque, MD
Professor of Medicine, University of Rochester School of Medicine and Dentistry, and Director AIDS Center
University of Rochester Medical Center

Presentation Date: 03/07/2010

Release Date: 03/07/2010

Course Overview

Learning Objectives

Describe common characteristics of Immune Reconstitution Inflammatory Syndrome (IRIS).
Outline the differential diagnosis of IRIS.
Discuss the management and the treatment of patients with IRIS.

Presenter Bio

Recent Changes in HIV Treatment Guidelines

Roy Gulick, MD, MPH
Professor of Medicine and Chief of the Division of Infectious Diseases
Weill Medical College of Cornell University in New York City

Presentation Date: 01/19/2010

Release Date: 01/19/2010

Co-sponsor:

Course Overview

Learning Objectives

Discuss the recent changes in antiretroviral treatment guidelines.
Understand the data used to support the recent guidelines changes.
Be aware of the controversies surrounding some of the recent guidelines changes.

Presenter Bio

Overdose Prevention: The Role of Naloxone in the Community

Sharon Stancliff, MD
Medical Director
Harm Reduction Coalition

Presentation Date: 12/08/2009

Release Date: 12/08/2009

Course Overview

Learning Objectives

Discuss the epidemiology of opioid overdose.
Advise their patients on how to avoid, recognize and act on opioid overdoses.
Discuss the role and safety of prescribing and distributing naloxone in the community.
Understand the NYS requirements to become an Opioid Overdose Prevention Program.

Presenter Bio

Post-Exposure Prophylaxis

Antonio Urbina, MD
Associate Medical Director
Center for Comprehensive Care, St. Luke's Roosevelt Hospital

Presentation Date: 11/19/2009

Release Date: 11/19/2009

Course Overview

Learning Objectives

Discuss the NYS Guidelines for post exposure prophylaxis (PEP).
State the definition of “significant” exposure.
Discuss management of the source patient.
Discuss post-exposure prophylaxis therapy and side effects.
Discuss the challenges associated with PEP.
Discuss follow-up care including labs, PEP, and counseling.

Presenter Bio

Antonio Urbina, MD is the Associate Medical Director of the Center for Comprehensive Care, an HIV program of St. Luke’s-Roosevelt Hospital in New York City that ensures continuity of care for over twelve hundred patients. Dr. Urbina is also the Medical Director of the PEP, Testing and Diagnosis Center of Excellence of NYSDOH AIDS Institute.

Disclosure of HIV to Perinatally Infected Children and Adolescents

Clinical Initiative

Presentation Date: 11/18/2009

Release Date: 11/18/2009

HBV & HIV: A Tale of Two Viruses and Many Drugs!

Douglas Dieterich, MD
Professor of Medicine
Mount Sinai School of Medicine

Presentation Date: 11/17/2009

Release Date: 11/17/2009

Co-sponsor:

Course Overview

Learning Objectives

Explain the importance of diagnosing and evaluating HIV / HBV coinfection.
Describe how to treat chronic hepatitis B in the setting of HIV coinfection.
Discern renal toxicity issues in treating HIV & HBV.
Explain the importance of screening for hepatocellular carcinoma (HCC) in HIV/HBV coinfected patients.

Presenter Bio

Douglas Dieterich, MD is Professor of Medicine in the Division of Hepatology with appointments in the divisions of Liver Disease, Gastroenterology and Infectious Diseases at Mount Sinai School of Medicine in New York City. Widely published, Dr. Dieterich is the author of numerous journal articles, abstracts and book chapters on viral hepatitis and AIDS-associated infections of the gastrointestinal tract and liver.

Acute HIV Infection: New Frontiers for HIV Prevention

Antonio Urbina, MD
Associate Medical Director
Center for Comprehensive Care, St. Luke's Roosevelt Hospital

Presentation Date: 11/10/2009

Release Date: 11/10/2009

Course Overview

Learning Objectives

To understand transmission dynamics and pathogenesis of HIV during initial infection as well as the public health importance of diagnosing acute HIV infection (AHI).
To recognize the signs and symptoms associated with acute HIV retroviral syndrome.
To explain participants how to establish diagnostic algorithms for acute HIV retroviral syndrome in their clinic settings.

Presenter Bio

ICAAC Update

Peter Ruane, MD
Private practice, Los Angeles, CA

Presentation Date: 11/05/2009

Release Date: 11/05/2009

Course Overview

Bivalent & Quadrivalent Human Papillomavirus Vaccines: The Current Status & Future Prospects for HIV Prevention

Jennifer Smith, PhD, MPH
Associate Professor
University of North Carolina

Presentation Date: 10/20/2009

Release Date: 10/20/2009

Co-sponsor:

Course Overview

Learning Objectives

Review clinical trials data to explain the efficacy of current generation HPV prophylactic vaccines.
Describe the association between increases in HPV infection and cervical cancer among HIV-seropositive individuals.
Explain the current data on associations between HPV status and HIV acquisition.

Presenter Bio

Jennifer S. Smith is an Associate Professor in Research within the Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina. Dr. Smith has conducted research on HPV and associated cervical neoplasia since 1995. Her current research focuses on epidemiological studies of human papillomavirus (HPV) and cervical cancer worldwide, with a focus on prevention via HPV self-screening and prophylactic vaccines.

Prevalence of Human Papillomavirus Infection & Efficacy of a Quadrivalent HPV Vaccine In Men

Stephen Goldstone, MD, FACS
Assistant Clinical Professor of Surgery
Mount Sinai School of Medicine

Presentation Date: 10/20/2009

Release Date: 10/20/2009

Co-sponsor:

Course Overview

Learning Objectives

Understand the efficacy of a quadrivalent HPV vaccine in men.
Understand the prevalence of HPV infection in young heterosexual men.
Understand the prevalence of HPV infection in young men who have sex with men.

Presenter Bio

HIV Testing of Defendants of Felony Sexual Assault

Clinical Initiative

Presentation Date: 10/01/2009

Release Date: 10/01/2009

HIV and Immigration

Clinical Initiative

Presentation Date: 10/01/2009

Release Date: 10/01/2009

International Perspectives on HIV Treatment Adherence and Drug Resistance

David Bangsberg, MD, MPH
Director
Massachusetts General Hospital (MGH) Center for Global Health

Presentation Date: 09/22/2009

Release Date: 09/22/2009

Co-sponsor:

Course Overview

Learning Objectives

Formulate adherence promoting strategies based on regimen specific HIV adherence, suppression, and resistance relationships, and how patient adherence levels lead to antiretroviral resistance.
Explain to HIV positive individuals how patterns of adherence influence risk of viral rebound.
Develop strategies to use social capital to improve adherence.

Presenter Bio

David Bangsberg is the Director of the Massachusetts General Hospital (MGH) Center for Global Health, Director of International Programs at the Ragon Institute of MGH, MIT and Harvard, co-director of the International Program for the Harvard University Center for AIDS Research. Dr. Bangsberg's research focuses on HIV antiretroviral adherence in poor regions of the world. He has also characterized the relationship between adherence and resistance to HIV antiretroviral therapy in a series of studies in HIV-infected homeless people in San Francisco.

HIV and Anal Cancer

Roberto Corales, DO
Senior Director of HIV Medicine and Clinical Research
AIDS Care, Rochester, NY

Presentation Date: 09/03/2009

Release Date: 09/03/2009

Course Overview

19th Annual HIV/AIDS Clinical Conference

HIV Treatment Update: What's New, Important, and Interesting in 2009

Paul Sax, MD
Associate Professor of Medicine and Clinical Director, HIV Program and Division of Infectious Diseases, Brigham and Women’s Hospital
Harvard Medical School

Presentation Date: 05/15/2009

Release Date: 05/15/2009

Course Overview

Learning Objectives

Discuss the current approach to antiretroviral therapy for HIV infection.
Explain advantages and disadvantages of regimens for initial therapy of HIV-1 infection.
Describe the goals of treatment in patients with highly drug-resistant HIV-1.

Presenter Bio

Paul E. Sax, MD, is Clinical Director of the HIV Program and Division of Infectious Diseases at Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School. Dr. Sax’s focus is HIV research, clinical practice, and teaching. His research interests include clinical trials of new antiretroviral therapies, complications of antiretroviral treatment, and the cost-effectiveness of HIV management strategies. Dr. Sax is the Principal Investigator of the Brigham and Women's Hospital AIDS Clinical Trials Unit and is a member of the Cost Effectiveness of Preventing AIDS Complications (CEPAC) Research Group. He is the Editor-in-Chief of the Journal Watch AIDS Clinical Care Editorial Board since 2003.

Mental Health Obstacles in HIV Care

Warren Ng, MD
Assistant Clinical Professor of Psychiatry
Columbia University

Presentation Date: 05/15/2009

Release Date: 05/15/2009

Course Overview

Learning Objectives

Discuss how depression works to worsen the HIV epidemic and limit treatment options for HIV-infected patients.
Explain how mental health vulnerabilities affect patients with HIV and strategies for treatment.
Explain the neuropsychiatric manifestations of HIV in the treatment of HIV infected patients.

Presenter Bio

Neuroprotective Strategies for HIV

Harris Gelbard, MD, PhD
Professor of Neurology, Pediatrics and Microbiology and Immunology
University of Rochester Medical Center

Presentation Date: 05/15/2009

Release Date: 05/15/2009

Course Overview

Learning Objectives

Describe the optimal trial designs for testing potential neuroprotective agents.
List agents currently under investigation for neuroprotection.
Discuss the future prospects for neuroprotection in HIV/AIDS.

Presenter Bio

Dr. Gelbard is the Director of the Center for Neural Development and Disease, and Professor of Neurology, Pediatrics and Microbiology & Immunology at the University of Rochester Medical Center. Dr. Gelbard has 25 years of experience as a molecular neuropharmacologist, working in experimental models of neuroAIDS and HIV-1 neuroinflammation since 1992. Dr. Gelbard is the leader of the NeuroAIDS research group and over the past several years has worked to develop new therapies for HIV-associated neurocognitive disorders (HAND).

HIV Care for Incarcerated Patients in New York State and Nationally: Are We Meeting the Standards?

Douglas Fish, MD
Medical Director, Division of HIV Medicine
Albany Medical College

Presentation Date: 05/15/2009

Release Date: 05/15/2009

Course Overview

Learning Objectives

State how HIV quality care is measured in NY State.
Define the mortality trend for HIV-infected, incarcerated patients in NY State.
Describe how HIV case conferencing and education is made available to practitioners in the NY State Correctional System.

Presenter Bio

Douglas Fish<cfif len(qPresenters.presenter_credential)>, MD</cfif>

Douglas Fish, MD is an HIV specialist at Albany Medical College. He is the Medical Director of the AIDS Treatment Center and the HIV Unit at Albany Medical Center, head of the Division of HIV Medicine, and assistant professor of medicine at Albany Medical College. Dr. Fish is faculty for the International AIDS Society and a member of the Medical Care Criteria Committee for the NYSDOH AIDS Institute. He provides HIV clinical education within the New York State Department of Corrections and Clinical Education Initiative, and is a member of the HIV Guidelines Committee for the Department. He is also a member of the Advisory Panel for the New York State AIDS Drug Approval Program (ADAP) and a member of the Infectious Disease Society of America.

Update on Liver Disease in HIV (Hepatitis B & HIV Coinfection)

Benedict Maliakkal, MD
Associate Professor of Medicine
University of Rochester Medical Center

Presentation Date: 05/15/2009

Release Date: 05/15/2009

Course Overview

Learning Objectives

Describe the epidemiology and modes of transmission of hepatitis B.
Discuss the appropriate evaluation and management of health care workers who have occupational exposure to hepatitis B virus.
Explain the clinical management of Hepatitis B and HIV coinfection.

Presenter Bio

Benedict J. Maliakkal, MD is an Associate Professor in the Department of Medicine, Division of Gastroenterology and Hepatology, University of Rochester Medical Center. He is certified in Gastroenterology, Hepatology, and Internal Medicine by the American Board of Internal Medicine. Dr. Maliakkal is consistently working to improve the treatment for digestive tract by combining medical research, education, and patient care. He has authored and co-authored numerous articles related to gastroenterology and transplant hepatology.

Update on Liver Disease in HIV (Hepatitis C & HIV Coinfection)

Benedict Maliakkal, MD
Associate Professor of Medicine
University of Rochester Medical Center

Presentation Date: 05/15/2009

Release Date: 05/15/2009

Course Overview

Learning Objectives

Describe the epidemiology and modes of transmission of hepatitis C (HCV).
Discuss screening and diagnostic workup of HCV infection.
Explain the clinical management of Hepatitis C and HIV coinfection.

Presenter Bio

HIV Post-Exposure Prophylaxis for Occupational and Non-occupational Exposure

Antonio Urbina, MD
Associate Medical Director
Center for Comprehensive Care, St. Luke's Roosevelt Hospital

Presentation Date: 05/15/2009

Release Date: 05/15/2009

Course Overview

Learning Objectives

Discuss the NYS Guidelines for Post Exposure Prophylaxis.
State the definition of "significant" exposure.
Discuss the management of the source patient.
Discuss post-exposure prophylaxis therapy and side effects.
Discuss the challenges associated with PEP.
Discuss follow-up care including labs, PEP, and counseling.

Presenter Bio

Antonio Urbina<cfif len(qPresenters.presenter_credential)>, MD</cfif>

NYSDOH Syphilis Guidelines: A Case Presentation

Amneris Luque, MD
Professor of Medicine, University of Rochester School of Medicine and Dentistry, and Director AIDS Center
University of Rochester Medical Center

Presentation Date: 01/01/2009

Release Date: 01/01/2009

Course Overview

Learning Objectives

State the frequency with which a health care provider should screen an HIV-infected patient for syphilis.
Discuss the criteria by which a health care provider should make a diagnosis of latent syphilis infection.
List the four conditions under which health care providers should perform a lumbar puncture in patients with syphilis or history of syphilis.

Presenter Bio